Company Performance - Myomo, Inc. reported a quarterly loss of $0.03 per share, better than the Zacks Consensus Estimate of a loss of $0.04, and an improvement from a loss of $0.06 per share a year ago, representing an earnings surprise of 25% [1] - The company posted revenues of $9.21 million for the quarter ended September 2024, exceeding the Zacks Consensus Estimate by 15.82%, and up from $5.08 million in the same quarter last year [2] - Over the last four quarters, Myomo has surpassed consensus EPS estimates two times and topped consensus revenue estimates three times [2] Stock Outlook - Myomo shares have declined approximately 21% since the beginning of the year, contrasting with the S&P 500's gain of 21.2% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.01 on revenues of $9.45 million, and for the current fiscal year, it is -$0.18 on revenues of $28.62 million [7] - The estimate revisions trend for Myomo is mixed, resulting in a Zacks Rank 3 (Hold), indicating expected performance in line with the market in the near future [6] Industry Context - The Medical - Products industry, to which Myomo belongs, is currently ranked in the top 36% of over 250 Zacks industries, suggesting that companies in the top 50% outperform those in the bottom 50% by more than 2 to 1 [8]
Myomo, Inc. (MYO) Reports Q3 Loss, Tops Revenue Estimates